Proposal to amend the distribution and access criteria for dasatinib (Sprycel)

18 December 2018 - PHARMAC is seeking feedback on a proposal to amend the distribution arrangements and access criteria for ...

Read more →

Proposal to harmonise, streamline and transition the Cancer Drug Implementation Advisory Committee to CADTH

14 December 2018 - Providing customised implementation support to decision-makers at all levels of the health system is a key ...

Read more →

Decision to list a new brand of iron polymaltose (Ferrosig)

11 December 2018 - PHARMAC is pleased to announce a decision to list a new brand of iron polymaltose inj ...

Read more →

Proposal to open access to atomoxetine and change funded brand

10 December 2018 - PHARMAC is proposing to remove all funding restrictions from all presentations of atomoxetine, and change the ...

Read more →

Proposal to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole

7 December 2018 - PHARMAC is seeking feedback on a multi-product proposal with Merck Sharpe & Dohme.  ...

Read more →

Proposal involving treatments for multiple sclerosis, narcolepsy and attention deficit hyperactivity disorder

30 November 2018 - PHARMAC is seeking feedback on a proposal involving the following products through a provisional agreement with ...

Read more →

Update on proposal to move to one funded brand of lamotrigine (Logem)

26 October 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to move to one ...

Read more →

Further update on proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C

24 October 2018 - This is a further update on the proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis ...

Read more →

Proposal on the funding of infliximab, rituximab and tocilizumab

6 September 2018 - PHARMAC is proposing to change how three hospital medicines are managed within the Pharmaceutical Schedule. ...

Read more →

Proposal to list sapropterin for use in pregnancy by women with phenylketonuria

30 August 2018 - PHARMAC is seeking feedback on a proposal to fund sapropterin tablets, a treatment for the rare ...

Read more →

Proposal to move to one funded brand of lamotrigine (Logem)

29 August 2018 - PHARMAC is seeking feedback on a proposed change to the funding of lamotrigine dispersible tablets used ...

Read more →

Update on proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)

27 August 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to fund glecaprevir and ...

Read more →

Proposal to change the funded brand of epoetin alfa

21 August 2018 - PHARMAC is seeking feedback on a proposed change to the funded brand of epoetin alfa [erythropoietin ...

Read more →

Proposal to list nintedanib (Ofev) and remove restrictions from tiotropium bromide (Spiriva)

20 August 2018 - PHARMAC is seeking feedback on a proposal to list nintedanib (Ofev) and remove the current funding ...

Read more →

Free access plan for 'revolutionary' drug that could eliminate Hepatitis C by 2030

1 August 2018 - What has been called a "revolutionary" hepatitis C drug could soon be available free-of-charge to all ...

Read more →